Compare AstraZeneca plc (AZN) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Southern Copper Corp — how do they compare? AstraZeneca plc trades at $158.74 (market cap $248.14B), while Southern Copper Corp trades at $193.42 (market cap $164.21B). The key difference: AstraZeneca plc is the larger of the two by market cap, and Southern Copper Corp pays the higher dividend (2.26%). Which is the better fit depends on your goals.
| AZN | SCCO | |
|---|---|---|
Market Cap | $248.14B | $164.21B |
Sector | Health | Basic Materials |
52-Week High | $209.48 | $218.85 |
52-Week Low | $147.06 | $93.70 |
Enterprise Value | $275.41B | $165.50B |
Dividend Yield | 2.01% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Southern Copper (SCCO) trades at $193.14, down 3.48% on the day, amid a broader copper price pullback. The stock exhibits strong fundamentals with revenue growth from $13.42B in 2025 to a projected $15.8B in 2026 and robust profitability margins, including a net income margin of 35.87%. Recent quarters have consistently beaten EPS estimates, and technical indicators show a bullish trend with key support at $191. However, the stock trades at a premium valuation with a P/E of 29.18, above the analyst consensus price target of $153.64.
The outlook for SCCO is mixed; strong earnings growth and exposure to copper demand from AI and data centers present upside, but high valuation and reliance on volatile metal prices pose risks. Analyst sentiment is cautious with only 10.34% buy ratings, suggesting limited near-term upside from current levels despite solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
